Solvonis Therapeutics PLC
SVNS.L operates in the healthcare diagnostics industry, providing products and services related to diagnostic testing and research.
Business. SVNS.L is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is listed on the London Stock Exchange under the ticker SVNS.L. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the pharmaceuticals and medical research sector.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
SVNS.L is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is listed on the London Stock Exchange under the ticker SVNS.L. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the pharmaceuticals and medical research sector.
SVNS.L maintains a strong liquidity position, with cash and equivalents amounting to $1.72 billion, significantly exceeding its total liabilities of $1.39 billion. The company's debt-to-equity ratio is 0.01, indicating a minimal reliance on debt financing and a robust equity base of $6.19 billion.
In terms of profitability, SVNS.L's financial metrics suggest a conservative capital structure and a focus on maintaining a strong balance sheet. The company's low debt levels and high cash reserves support its ability to fund operations and invest in growth opportunities without significant financial risk.
SVNS.L's revenue is primarily concentrated in the healthcare diagnostics segment, with no disclosed geographic breakdown. The company's business model is centered around this core segment, and there is no indication of significant diversification across multiple product lines or geographic regions.
The company's growth trajectory is not immediately evident from the available data, as there is no disclosed revenue history or outlook for the current or next fiscal year. However, the absence of capital expenditures suggests a current focus on maintaining operations rather than expanding through new investments.
SVNS.L's risk profile is characterized by low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags, and the number of shares outstanding remains unchanged between basic and diluted shares, indicating no near-term dilution pressure.
Recent events and filings do not provide specific details on SVNS.L's operational or strategic developments. The company's financial snapshot and risk assessment suggest a stable and conservative financial position, with no significant recent changes in its capital structure or risk profile.
- SVNS.L has a strong liquidity position with $1.72 billion in cash and equivalents.
- The company's debt-to-equity ratio is 0.01, indicating a minimal reliance on debt financing.
- SVNS.L's business is concentrated in the healthcare diagnostics segment with no disclosed geographic diversification.
- The company has no immediate liquidity or dilution risks, and its shares are not expected to be diluted in the near term.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,00 |
| Revenue | —no estimate | —no estimate | 0 |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Market Capmarket_price * shares_outstanding_diluted
- Enterprise Valuemarket_cap - net_cash
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- SVNS.L Market data — financials · 2026-05-29
- Solvonis Therapeutics PLC Market data — analyst estimates · 2026-05-29
Ownership & reference
Leadership
- Anthony TennysonChief Executive Officer, Executive Director